Literature DB >> 20464614

Fabry disease in patients with migraine with aura.

Beatrice Albano1, L Dinia, M Del Sette, C Gandolfo, G Sivori, C Finocchi.   

Abstract

Anderson-Fabry disease (AFD) is an X-linked recessive lysosomal disease caused by alpha-galactosidase A (alpha-gal) deficiency, causing progressive glycosphingolipid storage in various organ systems. Headache is a frequent symptom. Cerebral magnetic resonance imaging (MRI) often shows multiple white matter lesions (WML), like those seen in patients affected by migraine, in particular with aura (MA). To our knowledge, there are no reports about the prevalence of AFD in patients with MA. The objective of the study was to determine AFD prevalence, as assessed by alpha-gal activity and genetic tests, in MA patients. We evaluated 73 consecutive patients followed by the Headache Centre of our Department with a diagnosis of MA. They were screened for migraine characteristics and cerebrovascular risk factors. Gaseous contrast transcranial Doppler was used to diagnose right-to-left shunt and MRI to detect WML. All patients underwent blood test to evaluate peripheral alpha-gal activity and to identify alpha-gal gene mutations. Of 73 consecutive screened subjects (59 females, 14 males; mean age 38.3 +/- 11.8 years), the known GLA pathologic mutation p.[Asp313Tyr] was found in a 38-year-old woman, with a history of MA, deep venous thrombosis and abdominal pain. Cerebral MRI showed small WML. This is the first study reporting AFD prevalence in a cohort of MA patients. We found a relatively high prevalence (about 1.37%) among the examined patients, even if this finding needs to be confirmed in a larger sample. Despite this high prevalence, it seems not necessary to screen systematically all MA patients for AFD, but since it is a treatable genetic disorder, it is worthwhile to consider it for the subgroup of patients presenting WML and other typical AFD symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464614     DOI: 10.1007/s10072-010-0314-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  11 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

Review 2.  Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Bahi Takkouche; Francisco Caamaño Isorna; Ali Samii
Journal:  BMJ       Date:  2004-12-13

3.  A survey of the pain experienced by males and females with Fabry disease.

Authors:  Andrea L Gibas; Regan Klatt; Jack Johnson; Joe T R Clarke; Joel Katz
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

4.  Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

Authors:  Arndt Rolfs; Tobias Böttcher; Marlies Zschiesche; Peter Morris; Bryan Winchester; Peter Bauer; Uwe Walter; Eilhard Mix; Mathias Löhr; Klaus Harzer; Ulf Strauss; Jens Pahnke; Annette Grossmann; Reiner Benecke
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

5.  Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

Authors:  David F Moore; Gheona Altarescu; Geoffrey S F Ling; Neal Jeffries; Karen P Frei; Thais Weibel; Gustavo Charria-Ortiz; Raymond Ferri; Andrew E Arai; Roscoe O Brady; Raphael Schiffmann
Journal:  Stroke       Date:  2002-02       Impact factor: 7.914

6.  CNS manifestations of Fabry's disease.

Authors:  Andreas Fellgiebel; Matthias J Müller; Lionel Ginsberg
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

7.  The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.

Authors:  Markus Ries; Uma Ramaswami; Rossella Parini; Bengt Lindblad; Catharina Whybra; Ingrid Willers; Andreas Gal; Michael Beck
Journal:  Eur J Pediatr       Date:  2003-09-20       Impact factor: 3.183

Review 8.  Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis.

Authors:  Richard H Swartz; Ralph Z Kern
Journal:  Arch Neurol       Date:  2004-09

9.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

10.  Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.

Authors:  David F Moore; Gheona Altarescu; Peter Herscovitch; Raphael Schiffmann
Journal:  BMC Neurol       Date:  2002-06-18       Impact factor: 2.474

View more
  2 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

2.  Characteristics of Neurological Symptoms in Adult Japanese Patients with Fabry Disease.

Authors:  Jun Sawada; Naoki Nakagawa; Kohei Kano; Tsukasa Saito; Takayuki Katayama; Takaaki Sawada; Ken Momosaki; Kimitoshi Nakamura; Naoyuki Hasebe
Journal:  Intern Med       Date:  2021-01-15       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.